Status:
UNKNOWN
Study of Biological Markers in Children With Sickle Cell Disease
Lead Sponsor:
Queen Fabiola Children's University Hospital
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
6+ years
Phase:
NA
Brief Summary
Sickle cell disease is associated with significant morbi-mortality hence the interest in an early and targeted care. At present, there is no plasmatic marker able to identify infants at higher risk of...
Eligibility Criteria
Inclusion
- Patient aged less than 6 months
- Sickle cell syndrome SS, Sβthal or SC confirmed by hemoglobin electrophoresis
- Subjects legal representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to let participate their child in the study
Exclusion
- Congenital abnormality other than sickle cell disease except for a glucose-6-phosphate-deshydrogenase
- Prematurity
- Initiation of the following therapies before enrollment: chronic transfusion regimen or bone marrow transplantation
Key Trial Info
Start Date :
May 10 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT04839159
Start Date
May 10 2012
End Date
June 30 2021
Last Update
April 9 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Saint Pierre
Brussels, Belgium, 1000
2
Hôpital Universitaire Des Enfants Reine Fabiola
Brussels, Belgium, 1020
3
HIS - Site Etterbeek-Ixelles
Brussels, Belgium, 1050